CombiMatrix forms biothreat agents test deal:
This article was originally published in Clinica
Executive Summary
CombiMatrix has linked up with Science Applications International to develop microarrays for identifying multiple biothreat organisms. Both companies have US Department of Defense (DoD) contracts supporting the development of complementary products. Leveraging these DoD funds can help expedite the development and testing of new identification and diagnostic assays for conventional biothreat agents and emerging and genetically engineered pathogens, said Mukilteo, Washington-based CombiMatrix. Under the collaboration, Science Applications' bioinformatics know-how will be combined with CombiMatrix' multiplexed microarray technology. CombiMatrix said that under the DoD contract, it was developing electrochemical detection as an alternative to the current use of large and expensive optical readers and dyes used in fluorescence detection.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.